Evidence map›Paper›PMID 38827239›Full record

ReviewBiomarker insights2024

The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers.

Seema Mustafa, Caroline S Jansen, Yash Jani, Sean Evans, Tony Z Zhuang, Jacqueline Brown, Bassel Nazha, Viraj Master, Mehmet Asim Bilen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker insights, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Seema MustafaEmory University School of Medicine, Atlanta, GA, USA.
Caroline S JansenEmory University School of Medicine, Atlanta, GA, USA.
Yash JaniMercer University, Macon, GA, USA.
Sean EvansEmory University School of Medicine, Atlanta, GA, USA.
Tony Z ZhuangEmory University School of Medicine, Atlanta, GA, USA.
Jacqueline BrownWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Bassel NazhaWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Viraj MasterWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Mehmet Asim BilenWinship Cancer Institute of Emory University, Atlanta, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past decade, immune checkpoint inhibitors (ICI) have been approved for treatment of genitourinary malignancies and have revolutionized the treatment landscape of these tumors. However, despite the remarkable success of these therapies in some GU malignancies, many patients' tumors do not respond to these therapies, and others may experience significant side effects, such as immune-related adverse events (iRAEs). Accordingly, biomarkers and improved prognostic tools are critically needed to help predict which patients will respond to ICI, predict and mitigate risk of developing immune-related adverse events, and inform personalized choice of therapy for each patient. Ongoing clinical and preclinical studies continue to provide an increasingly robust understanding of the mechanisms of the response to immunotherapy, which continue to inform biomarker development and validation. Herein, we provide a comprehensive review of biomarkers of the response to immunotherapy in GU tumors and their role in selection of therapy and disease monitoring.

Indexed as

avelumabbiomarkerImmune checkpoint inhibitornivolumabpembrolizumab

Identifiers

PMID38827239
PMCPMC11143877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.